financetom
Business
financetom
/
Business
/
Specialty insurance provider Kemper flips to Q3 loss despite revenue beat
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Specialty insurance provider Kemper flips to Q3 loss despite revenue beat
Nov 5, 2025 2:46 PM

Overview

* Kemper Q3 revenue rose and beat analyst expectations, driven by higher earned premiums

* Company flipped to net loss of $21 mln from net income last year amid elevated expenses related to policyholders' benefits

* Adjusted net operating income for Q3 fell significantly from the previous year

Outlook

* Company is taking actions to improve profitability and growth in Specialty P&C segment

* Company remains confident in its strategy despite challenging quarter

Result Drivers

* SPECIALTY P&C PRESSURE - Specialty Property & Casualty segment faced higher claim severity and adverse prior year development, reducing operating income

* LIFE INSURANCE GAINS - Life Insurance segment saw increased net operating income due to favorable mortality and expense management

* EARNED PREMIUMS INCREASE - Revenue rise driven by higher earned premiums in Specialty P&C, offset by reductions in non-core operations

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $1.24 $1.12

Revenue bln bln (4

Analysts

)

Q3 EPS -$0.34

Q3 Net -$21 mln

Income

Q3 $20.40

Adjusted mln

Consolid

ated Net

Operatin

g Income

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the property & casualty insurance peer group is "buy."

* Wall Street's median 12-month price target for Kemper Corp ( KMPR ) is $72.00, about 39.2% above its November 4 closing price of $43.75

* The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 9 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Delek US Insider Sold Shares Worth $337,778, According to a Recent SEC Filing
Delek US Insider Sold Shares Worth $337,778, According to a Recent SEC Filing
Mar 24, 2026
05:58 AM EDT, 03/24/2026 (MT Newswires) -- Shlomo Zohar, Director, on March 19, 2026, sold 7,343 shares in Delek US Holdings ( DK ) for $337,778. Following the Form 4 filing with the SEC, Zohar has control over a total of 6,646 common shares of the company, with 6,646 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1694426/000149140326000006/xslF345X05/wk-form4_1774310072.xml ...
Market Chatter: Equinor Seeks Marcellus Shale Gas Expansion After Global Portfolio Reorganization
Market Chatter: Equinor Seeks Marcellus Shale Gas Expansion After Global Portfolio Reorganization
Mar 24, 2026
05:51 AM EDT, 03/24/2026 (MT Newswires) -- Equinor ( EQNR ) is seeking to broaden its US shale gas operations after a reorganization of its worldwide assets, Bloomberg News reported Monday, citing an interview with Vice President for International Exploration and Production Philippe Mathieu. The energy business is primarily exploring opportunities around the Marcellus region to build upon its existing...
Ionis Pharmaceuticals Insider Sold Shares Worth $412,486, According to a Recent SEC Filing
Ionis Pharmaceuticals Insider Sold Shares Worth $412,486, According to a Recent SEC Filing
Mar 24, 2026
05:56 AM EDT, 03/24/2026 (MT Newswires) -- Eugene Schneider, EVP, Chief Clinical Development Officer, on March 19, 2026, sold 5,812 shares in Ionis Pharmaceuticals ( IONS ) for $412,486. Following the Form 4 filing with the SEC, Schneider has control over a total of 63,890 common shares of the company, with 63,890 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/874015/000087401526000152/xslF345X05/primary_doc.xml ...
Composition Wealth Welcomes $900 Million Edgewater Wealth Management, Expanding Firm's Northwest Footprint
Composition Wealth Welcomes $900 Million Edgewater Wealth Management, Expanding Firm's Northwest Footprint
Mar 24, 2026
 Team joins national firm for greater growth opportunities, expanded investment capabilities and client resources LOS ANGELES, March 24, 2026 /PRNewswire/ -- Composition Wealth, a nationally registered investment advisor (RIA) enterprise with over $10 billion in assets and 125 employees nationwide, today announced a merger with Edgewater Wealth Management (Edgewater) of Tacoma, Washington. The Edgewater team of 16, including eight wealth advisors,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved